Antimicrobial resistance and bovine respiratory disease; a pharmacokinetic/pharmacodynamic approach to macrolide resistance

dc.contributor.authorDeDonder, Keith David
dc.date.accessioned2015-12-21T14:54:33Z
dc.date.available2015-12-21T14:54:33Z
dc.date.graduationmonthMayen_US
dc.date.issued2016-05-01en_US
dc.date.published2016en_US
dc.description.abstractBovine respiratory disease (BRD) remains a major disease in beef production systems. The administration of antimicrobials for both the control and treatment of acute BRD is common. According to most published accounts, antimicrobial resistance among BRD pathogens is increasing; therefore, judicious antimicrobial usage is vital for continued efficacy. The introduction of a novel antimicrobial class has not occurred for well over a decade, therefore it is paramount to maximize efficacy of the antimicrobials currently available. The challenge is targeting the perfect scenario: maximizing clinical efficacy while minimizing antimicrobial resistance. The host-pathogen-drug interaction is very complex and despite current sophisticated technology, this interaction is still not well understood for many infectious diseases. This dissertation work sought to investigate the effects of the administration of a macrolide for both control and treatment of acute BRD on the prevalence of resistance among isolated Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. Whole genome sequencing of M. haemolytica was utilized to investigate the presence/absence of macrolide resistance genes and their relationship to the observed minimum inhibitory concentration. Cattle were sampled (plasma and pulmonary epithelial lining fluid) after administration of gamithromycin for drug concentration analysis. A non-linear mixed effects approach was used to fit a compartmental model to the resulting sparse pharmacokinetic data so that a complete time concentration curve could be simulated. From these curves, the CMAX and AUC were measured and used to calculate standard PKPD indices using the MIC values of the isolated bacteria. Clear associations between the use of gamithromycin for control and treatment of BRD and a statistically significantly increased likelihood of macrolide resistance were not found, possibly due to sample size limitations. The calculation of pharmacokinetic-pharmacodynamic indices found that a longer drug exposure was more closely associated with a successful treatment outcome, but there was not a statistically significant correlation. However, there were few clinical failures in this study giving further credence to the complexity of the in vivo system. There are many factors beyond pharmacokinetics/pharmacodynamics and MICs that contribute to the success of a treatment regimen for cattle suffering from BRD.en_US
dc.description.advisorMichael D. Apleyen_US
dc.description.degreeDoctor of Philosophyen_US
dc.description.departmentDiagnostic Medicine/Pathobiologyen_US
dc.description.levelDoctoralen_US
dc.identifier.urihttp://hdl.handle.net/2097/20602
dc.language.isoenen_US
dc.publisherKansas State Universityen
dc.subjectbovine respiratory diseaseen_US
dc.subjectantimicrobial resistanceen_US
dc.subjectgamithromycinen_US
dc.subjectpharmacokineticen_US
dc.subjectpharmacodynamicen_US
dc.subjectminimum inhibitory concentrationen_US
dc.subject.umiVeterinary Medicine (0778)en_US
dc.titleAntimicrobial resistance and bovine respiratory disease; a pharmacokinetic/pharmacodynamic approach to macrolide resistanceen_US
dc.typeDissertationen_US

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
KeithDeDonder2016.pdf
Size:
3.31 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.62 KB
Format:
Item-specific license agreed upon to submission
Description: